BioCentury | Feb 13, 2020
Finance
Feb. 12 Financial Quick Takes: Trio of follow-ons; plus Teva, PentixaPharm, Inotrem
...With its €15 million ($16.5 million) series A led by ELSA Eckert Life Science Accelerator, PentixaPharm GmbH...
...4 TREM1 - Triggering receptor expressed on myeloid cells 1 BioCentury Staff Adverum Biotechnologies Inc. Theravance Biopharma Inc. Inotrem S.A. PentixaPharm GmbH...
...4 TREM1 - Triggering receptor expressed on myeloid cells 1 BioCentury Staff Adverum Biotechnologies Inc. Theravance Biopharma Inc. Inotrem S.A. PentixaPharm GmbH...
